oru.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Entacapone and prostate cancer risk in patients with Parkinson's disease
EPID Research Oy, Espoo, Finland.
Orion Corporation, Orion Pharma, Espoo, Finland.
EPID Research Oy, Espoo, Finland.
EPID Research Oy, Espoo, Finland.
Show others and affiliations
2015 (English)In: Movement Disorders, ISSN 0885-3185, E-ISSN 1531-8257, Vol. 30, no 5, p. 724-728Article in journal (Refereed) Published
Abstract [en]

Background: The association between Parkinson’s disease (PD) and prostate cancer, both common in elderly men, is disputable. In the STRIDE-PD study, prostate cancer developed in 9 patients (3.7%) receiving levodopa/carbidopa with entacapone, a catechol-O-methyltransferase inhibitor, versus 2 cases (0.9%) without entacapone. The current pharmacoepidemiological study aimed to determine whether entacapone increases prostate cancer incidence or mortality in PD patients and whether cumulative exposure affects these rates.

Methods: We performed a retrospective cohort study using population-wide health care registers with patientlevel linkage. Prostate cancer incidence and mortality were modeled by Cox’s proportional hazards models.

Results and Conclusions: Use of entacapone with Ldopa/dopa decarboxylase inhibitor caused no increased risk of prostate cancer incidence (hazard ratio [HR]: 1.05; 95% confidence interval: 0.76-1.44) or mortality (0.93; 0.43-1.98). The HR for cumulative entacapone use of >360 days versus never-use was 0.82 (0.56-1.18) for prostate cancer incidence and 1.27 (0.60-2.72) for prostate cancer mortality.

Place, publisher, year, edition, pages
Hoboken, USA: Wiley-Blackwell, 2015. Vol. 30, no 5, p. 724-728
Keywords [en]
Entacapone, evodopa, prostate cancer, pharmacoepidemiology
National Category
Medical and Health Sciences Cancer and Oncology
Identifiers
URN: urn:nbn:se:oru:diva-47313DOI: 10.1002/mds.26140ISI: 000352790700018PubMedID: 25639262Scopus ID: 2-s2.0-84926985571OAI: oai:DiVA.org:oru-47313DiVA, id: diva2:890642
Available from: 2016-01-04 Created: 2016-01-04 Last updated: 2017-12-01Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Search in DiVA

By author/editor
Tuvblad, Catherine
By organisation
School of Law, Psychology and Social Work, Örebro University, Sweden
In the same journal
Movement Disorders
Medical and Health SciencesCancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 301 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf